Security key
005083100
ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.000001 per share (ACTU)
CUSIP: 005083100
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.000001 per share
- Total 13F shares
- 13,110,237
- Total 13F value
- $80,234,480
- Share change
- +1,089,796
- SEC-reported price per share
- $6.12
- Number of holders
- 44
- Value change
- +$6,660,093
- Number of buys
- 29
- Number of sells
- 12
- Shares outstanding
- 23,561,857
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
44
Top holders
10
ACTU full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
ACTUATE THERAPEUTICS, INC. SEC filings
ACTUATE THERAPEUTICS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 005083100
Recent filing periods:
Ownership snapshot
Top reported holders of ACTU - ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.000001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOS Fund I, LP
Disclosed value leader
BIOS Fund I, LP
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 50%
13D/G row: BIOS Fund I, LP
Showing 1-6 of 15 holder rows.
Quick read
BIOS Fund I, LP leads the comparable SEC ownership view at 50%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOS Fund I, LP's linked filing trail.
Comparable ownership
Top 5
BIOS Fund I, LP
50%
BIOS Capital Management, LP
43%
Voss Capital, LP
3.8%
VANGUARD GROUP INC
1.3%
BlackRock, Inc.
1.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOS Fund I, LP |
13D/G
AARON G.L. FLETCHER
|
50%
|
$112,734,207
10,267,232 shares
|
+$1,733,259 | 27 Jun 2025 |
| BIOS Capital Management, LP |
13F
Company
|
43%
|
$67,234,473
10,049,996 shares
|
— | 30 Sep 2025 |
| Voss Capital, LP |
13F
Company
|
3.8%
|
$5,996,100
896,278 shares
|
— | 30 Sep 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.3%
|
$2,114,107
316,010 shares
|
— | 30 Sep 2025 |
| BlackRock, Inc. |
13F
Company
|
1.2%
|
$1,887,075
282,074 shares
|
— | 30 Sep 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.62%
|
$972,805
145,412 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
44
Shares
13,110,237
Rows available
44
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
42
Q4 2025 holders
44
Holder diff
2
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend